DEF: Adagio Medical 2026 Annual Meeting Proxy Statement

Adagio Medical Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, at 10:00 a.m. Pacific Time.
• Stockholders will vote on the election of two Class II directors: Orly Mishan and Sean Salmon.
• Stockholders will vote on the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for voting is April 24, 2026, with 22,210,459 shares of common stock outstanding and entitled to vote.
• The company is an emerging growth company and is exempt from certain executive compensation disclosure requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a standard administrative filing for an annual meeting, reflecting the company's transition post-business combination and its ongoing efforts to stabilize leadership and capital structure.

Positives

• The company has successfully completed a business combination and subsequent PIPE financings to bolster its capital position.
• The Board has established independent Audit, Compensation, and Nominating and Corporate Governance committees to ensure proper oversight.
• The company has adopted a Clawback Policy to align executive compensation with financial reporting integrity.
• The company maintains a policy prohibiting hedging and pledging of its equity securities by directors and officers.

Negatives

• The company reported significant executive turnover in 2025, including the departure of the former COO and former CFO.
• The company has incurred substantial costs related to the business combination and ongoing financing activities.
• The company is subject to potential cash penalties if it fails to meet registration statement filing deadlines for shares issued in private placements.

Risks

• The company faces risks related to its status as an emerging growth company and the potential for future dilution of common stock.
• The company is dependent on successful equity financings or business development transactions to meet its financial goals.
• The company's ability to maintain the effectiveness of registration statements is critical to avoiding potential cash penalties.
• The company faces risks associated with the volatility of its share price and the potential for future capital raises.

Future Outlook

The company intends to focus on achieving financing goals during 2026, which are tied to the payment of deferred annual cash performance bonuses for the CEO and CFO.

Management Comments

• The Board believes that the separation of the Chair and Chief Executive Officer roles reinforces the independence of the Board in its oversight of the business.
• The Board believes that the current leadership structure is appropriate and enhances its ability to effectively carry out its roles and responsibilities.

Industry Context

StockSavvy.ai notes that Adagio Medical is operating in the competitive cardiovascular medical technology sector, where companies frequently utilize SPAC mergers and PIPE financings to fund R&D and commercialization efforts. The focus on experienced leadership from major industry players like Medtronic and Boston Scientific is a common strategy to navigate regulatory and commercial hurdles.

Comparison to Industry Standards

• The company's board composition and committee structure align with standard practices for Nasdaq-listed medical technology companies.
• The use of equity-based compensation, including stock options with multi-year vesting, is consistent with industry norms for retaining executive talent in the life sciences sector.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company engaged in multiple PIPE financings and convertible security financings involving entities affiliated with Perceptive Advisors LLC, a major stockholder.
• The company entered into registration rights agreements with various investors in connection with these financings.

Stakeholder Impact

• Shareholders are requested to vote on director elections and auditor ratification.
• The company's financing activities and potential future capital raises may impact share dilution.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 16, 2026.
• Tabulate and announce voting results.
• File a Form 8-K with the final voting results within four business days after the meeting.

Key Dates

Keywords

Adagio Medical, Proxy Statement, Annual Meeting, Medical Technology, Corporate Governance, Executive Compensation, SEC Filing